Advertisement.

VVUS Projected Dividend Yield

Vivus Inc ( NASDAQ : VVUS )

VIVUS is a pharmaceutical company with three approved therapies and one product candidate in active clinical development. PANCREAZE® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Qsymia® (phentermine and topiramate extended release) is approved by FDA for chronic weight management. STENDRA® (avanafil) is approved by FDA for erectile dysfunction (ED) and by the European Commission under the trade name SPEDRA, for the treatment of ED in the European Union. VI-0106 (tacrolimus) is in active clinical development and is being studied in patients with pulmonary arterial hypertension.

20 YEAR PERFORMANCE RESULTS

VVUS Dividend History Detail
VVUS Dividend News
VVUS Competitors News

# of Shares: 0

Closing Price: 0.47

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000